NCT00236353 – An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder Posted on March 18, 2019 by tsuperadmin -
NCT00269919 – Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia Posted on March 18, 2019 by tsuperadmin -
NCT00216528 – A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta) Posted on March 18, 2019 by tsuperadmin -
NCT00246246 – A Randomized, Open-label Trial of RISPERDAL® CONSTA™ Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder Posted on November 2, 2016 by tsuperadmin -
NCT00216580 – An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis Posted on August 3, 2015 by tsuperadmin -
NCT00216476 – CONSTATRE: Risperdal® Consta® Trial of Relapse Prevention and Effectiveness Posted on August 3, 2015 by tsuperadmin -
NCT00266552 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00250354 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00236470 – Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders – an Open Label Follow-up Trial of CR002020 Posted on October 20, 2014 by tsuperadmin -
NCT00236444 – Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders Posted on October 20, 2014 by tsuperadmin -
The YODA Project